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Abstract 
Background: Survival and relapse after gastric cancer surgery are largely 
attributed to tumor biology and surgical radicality, yet other prognostic factors 
have been reported, including respiratory sepsis and anastomotic leakage, 
but not global morbidity severity score (MSS). The hypothesis tested was that 
MSS would be associated with both disease-free (DFS) and overall survival 
(OS). 
Methods: Consecutive 373 patients undergoing potentially curative surgery for 
gastric adenocarcinoma between 2004 and 2016 in a UK cancer network 
were studied. Complications were defined prospectively as any deviation from 
a pre-determined post-operative course within 30 days of surgery, and 
classified according to the Clavien-Dindo severity classification (CDSC). 
Primary outcome measures were DFS and OS. 
Results: Post-operative complications were identified in 127 (34.0%) patients, 
which was associated with 9 (2.4%) post-operative deaths. Five-year DFS 
and OS were 35.9% and 38.5% for patients with a post-operative complication 
compared with 59.5% and 61.5% in controls (p<0.001, p=0.001 respectively). 
On multivariable DFS analysis, post-operative morbidity [Hazard Ratio (HR) 
1.63, 95% Confidence Interval (CI) 1.06-2.50, p=0.026] was independently 
associated with poor survival. On multivariable OS analysis, post-operative 
morbidity HR 2.25 (95%CI 1.04-4.85, p=0.039) and CDSC HR 1.76 (95%CI 
1.35-2.29, p<0.001) were independently associated with poor survival. These 
associations were also observed in patients with TNM stage I&II disease with 
morbidity HR 7.06 (95%CI 1.89-26.38, p=0.004) and CDSC HR 2.93 (95%CI 
1.89-4.55, p<0.001) offering independent prognostic value. 
Conclusion: Post-operative CDSC was an important independent prognostic 
factor after potentially curative gastrectomy for carcinoma associated with 
both DFS and OS. Prehabilitation strategies to minimize complications are 
warranted. 
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Introduction 
Positive versus negative outcomes after surgery are now commonly 
cited as the definitive measure of surgeon level competence, and certainly 
any reasonable observer would surely agree that fatal complications, though 
uncommon, represent an important measure of outcome at surgeon, hospital 
unit, and network level. In contrast, early post-operative morbidity has by 
tradition been considered to constitute a temporary blip in progress, with no 
long term adverse sequelae, other than an associated prolonged duration of 
hospital stay, and associated short term, poorer quality of life. Yet, some have 
contended that such morbidity, particularly after complex major 
gastrointestinal surgery, is associated with longer-term prognosis, disease 
relapse, and even cumulative survival.[1-3]  
In global terms, gastric cancer is the third leading cause of cancer 
related death, accounting for some 740,000 deaths annually.[4] Surgery 
remains the only potentially curative treatment, but recurrence and metastasis 
occur in as many as 20 to 60 % of patients, and survival remains poor even 
after curative resection. Moreover, such surgery is complex major in nature, 
inherently high risk, with operative morbidity and mortality cited in the most 
recent UK National Oesophagogastric Cancer Audits [5-6] to be 19.4 and 
1.9% respectively. Gastric cancer relapse and survival are largely attributed to 
tumor biology, aggressiveness, and the radicality of the surgery [7], but other 
prognostic factors have also been reported, in particular anastomotic leakage 
[3] and sepsis, after surgery for advanced gastric cancer. Why anastomotic 
leakage affects prognosis remains open to speculation; however, it has been 
argued that prolonged inflammatory response may promote the metastasis of 
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residual tumor cells. It might also be argued that any stimulus provoking a 
systemic inflammatory response results in similar adverse outcomes. The aim 
of this study was to determine if overall post-operative morbidity severity 
classification might influence prognosis. The hypothesis was that Clavien-
Dindo morbidity severity classification would be associated with both disease-
free and overall survival. The setting was a regional UK cancer network 
serving a population of 1.8 million. 
Method 
Patients 
In order to test the hypotheses proposed in this study, a single cohort 
was developed and included patients with radiological TNM stage I to III, who 
following staging were deemed to have potentially resectable gastric cancer 
between January 2004 and December 2016. All patients were managed by a 
multidisciplinary team with an interest in gastric cancer and included 
surgeons, oncologists, radiologists, anaesthetists and pathologists. 
Preoperative staging involved computed tomography (CT) of the thorax, 
abdomen and pelvis, including staging laparoscopy when considered 
appropriate, in order to facilitate individually patient tailored management 
plans. Selective use of neoadjuvant chemotherapy was adopted following 
publication of the Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy (MAGIC) Trial [8] in the latter part of the study and was 
prescribed to 74 patients with minimal comorbidities who were deemed to 
have relatively advanced disease and would benefit from down-staging of the 
tumour prior to surgery. Chemotherapy was administered for 3 or 4 cycles 
preoperatively and postoperatively. Each cycle consisted of epirubicin (50 
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mg/m2) by intravenous bolus, cisplatin (60 mg/m2) as a 4-hour infusion on day 
one and 5-fluorouracil (200 mg/m2/day) daily by a continuous intravenous 
infusion. 
The type of surgery for gastric cancer was determined by the 
anatomical location of the tumour; subtotal gastrectomy was performed in 
patients with antral tumours and total gastrectomy was performed in patients 
with tumours of the cardia (Siewert type III), body and linitis plastica. A 
modified extended D2 lymphadenectomy (preserving pancreas and spleen 
where possible) was performed and the operative approach was open in all 
cases. In 2010 an enhanced recovery after surgery program was introduced, 
the details of which have been described previously.[9] 
Ethical approval was sought, but the chair of Cardiff & Value University 
Health Board ethics committee confirmed that individual patient consent was 
not required to report clinical outcomes alone, and no formal approval was 
necessary. 
Clinicopathological characteristics 
Tumours were staged using the seventh edition of the AJCC/UICC-
TNM staging system.[10] Pathological factors were recorded from pathology 
reports issued at the time of surgery and included tumour differentiation, 
vascular invasion, margin status and the number of lymph nodes with and 
without metastasis. 
Complications were defined prospectively as any deviation from a pre-
determined post-operative course within 30 days following surgery. Patients 
undergoing a total gastrectomy underwent a gastrograffin swallow on post-
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operative day 5 to 7. Complications were diagnosed clinically based on 
observation, examination and supplementary investigations including but not 
limited to blood testing (haematology and biochemistry), radiology and 
microbiology. Once identified, complications were classified according to the 
Clavien-Dindo severity classification (CDSC).[11] Grade I includes patients 
with any deviation from normal post-operative course. Grade II complications 
are treated solely by medicinal therapies. Grade III complications require 
physical intervention. Grade IV complications are deemed life threatening 
requiring admission to the critical care unit. Grade V represents post-operative 
death. 
Patients were followed up at regular intervals of 3 months for the first 
year and 6 months thereafter. At each visit, patient underwent physical 
examination and blood analysis (haematology and biochemistry). Endoscopy 
and CT were performed when recurrent disease was suspected. In the event 
that patients developed symptoms suggestive of recurrent disease, 
investigations were undertaken sooner. Follow-up surveillance was conducted 
for 5 years or until death whichever was sooner. Death certification was 
obtained from the Office for National Statistics via Cancer Network 
Information System Cymru (CaNISC). Patterns of recurrence were defined as 
locoregional, distant (metastatic), or both locoregional and distant, when both 
were diagnosed at the same time. The time of recurrence was taken as the 
date of the confirmatory investigation. 
Statistical analysis 
Justification of sample size 
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Sample size calculations were based on a pre study literature survey of 
(CRUK cancers statistics reference), which indicated that the baseline 5-year 
survival rate of patients diagnosed with stage I gastric cancer was expected to 
be 80%, compared with 60% in patients with stage II gastric cancer, and a 
15% difference in survival would be a realistic expectation. Thus, a minimum 
of 276 patients were to be studied, providing 80% power to detect such a 
difference with p<0.05. 
Methods of data analysis 
Grouped data were expressed as median (range) and non-parametric 
methods were used throughout. Patient demographics were analyzed 
between the treatment modalities by means of χ2 or non-parametric tests 
including Mann - Whitney U test. These tests were also employed in the 
analysis of disease recurrence and time to recurrence for the treatment 
groups. Overall survival was calculated from time of diagnosis to the date of 
death. This approach was adopted in previous randomized trials [8] to allow 
for the variable interval to surgery following diagnosis, depending on whether 
neoadjuvant therapy was prescribed. Disease free survival was measured 
from the date of surgery until the date of recurrence or date of censoring. The 
median follow-up was 60 months (range 6 to 60), with 273 patients (73%) 
followed up for 5 years or until death. No patients were lost to follow-up. 
Cumulative survival was calculated according to the method of Kaplan and 
Meier; differences between groups were analyzed with the log rank test. 
Univariable analyses examining factors influencing survival were examined 
initially by the life table method of Kaplan and Meier, and those with 
associations found to be significant (p<0.100) were retained in a Cox 
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proportional hazards model using forward conditional methodology to assess 
the prognostic value of individual variables. All statistical analysis was 
performed in SPSS® (IBM® SPSS® Statistics v23.0.0.0, IBM Corporation, 
Armonk, New York, USA) with extension R. 
 
Results 
Patients, clinicopathological factors and post-operative morbidity 
In total, 373 patients were identified who underwent surgery for gastric 
cancer. The complete baseline characteristics of all clinicopathological 
variables studied can be found in table 1. The median age for patients 
undergoing resection was 69 years (inter-quartile range (IQR) 55 - 83) with 
the majority (43.7%) aged between 65 and 75 years. The majority of patients 
were male (68.1%), had distal cancers (43.7%), and were lymph node positive 
(55.2%). The median lymph node yield was 16 (range 3-64) with an inter-
quartile range of 13. Neoadjuvant chemotherapy was prescribed to 74 
patients (19.8%), and 78 patients (20.9%) received post-operative adjuvant 
chemotherapy (table 1). There were 127 (34.0%) patients who developed 
post-operative complications, which were associated with 9 (2.4%) post-
operative deaths within 90 days of surgery and 4 (1.1%) within 30 days of 
surgery. There were 74 (19.8%) infective and 22 (5.9%) non-infective 
complications (table 2). Post-operative complications were associated with 
proximal tumour location (p=0.013), higher pN category (p=0.016), higher 
pTNM stage (p=0.038), vascular invasion (p=0.008), higher R1 status 
(p<0.001), but not neoadjuvant (p=0.634) or adjuvant (p=0.804) therapy (table 
3). The median in-hospital length of stay (LOS) was 13 days (IQR 5 – 21). 
 10 
The median in-hospital LOS for CDSC 0 was 11 days (IQR 7 – 15), CDSC 1 
was 16 days (IQR 8 – 24), CDSC 2 was 17 days (IQR 9 – 26), CDSC 3 was 
24 days (IQR 10 – 38), CDSC 4 was 26 days (IQR 0 – 92) and CDSC 5 was 9 
days (IQR 0 – 35). During follow-up, 93 patients (24.9%) developed cancer 
recurrence and 150 patients (40.2%) died. 267 patients (71.6%) were followed 
up for 5 years or until death (median 60 (6-60) months) and no patients were 
lost to follow-up.  
Relationships between post-operative complications and disease free survival 
A univariable analysis of factors associated with disease free survival 
can be found in table 4. On multivariable analysis, pT category (Hazard Ratio 
(HR) 1.80 (95% Confidence Interval (CI) 1.35 - 2.39, p<0.001), vascular 
invasion (HR 1.87 (1.17 - 2.97), p=0.008), R1 status (HR 2.14 (1.32 - 2.50), 
p=0.002) and post-operative complication (HR 1.63 (1.06 - 2.50), p=0.026) 
were independently associated with disease free survival (table 4). Five-year 
disease free survival was 66.0% for patients without a complication compared 
with 34.0% for patients developing a post-operative complication (table 1). 
Patients were stratified into pTNM stage I & II, or pTNM stage III 
disease. Post-operative complication was associated with poorer disease free 
survival (p=0.038, figure 2a) in TNM stage I&II disease, but not in stage III 
disease (p=0.158, figure 2c). On multivariable analysis, post-operative 
complication was not independently associated with poorer disease free 
survival when confounded for other statistically significant factors (table 5). 
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Relationship between post-operative complications and overall survival 
A univariable analysis of factors associated with overall survival can be 
found in table 4. On multivariable analysis only pT category (HR 1.67 (1.34 - 
2.06), p<0.001), vascular invasion (HR 1.76 (1.21 - 2.55), p=0.003), post-
operative complication (HR 2.25 (1.04 - 4.85), p=0.039), and Clavien-Dindo 
classification (HR 1.76 (1.35 - 2.29), p<0.001) were independently associated 
with poor overall survival (table 4). 
Patients were stratified into TNM stage I & II, or TNM stage III disease. 
Post-operative complication was associated with poorer overall survival in 
TNM stage I&II disease (p=0.001, figure 2b), and stage III disease (p=0.007, 
figure 2d). On multivariable analysis, post-operative complication was only 
independently associated with poorer overall survival in patients with stage 
I&II disease (HR 7.06 (1.89 - 26.38), p=0.004) (Table 5a). Non-infective 
complications were associated with poorer overall survival in stage III disease 
(HR 2.24 (1.10 - 4.53), p=0.025) (table 5a). Clavien-Dindo classification was 
also independently associated with poor overall survival in stage I&II disease 
(HR 2.93 (1.89 - 4.55); p<0.001) and stage III disease (HR 1.21 (1.04 - 1.42); 
p=0.015) (table 5b). 
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Discussion 
Surgical outcomes, in broad terms have never been better or more 
transparent, despite the contemporary challenges of an increasingly elderly, 
comorbid, and sometimes frail population. High-risk surgical patients are at 
greater danger of postoperative complications, prolonged durations of hospital 
stay, and recovery in general blighted by a compromised quality of life. 
Moreover, patients diagnosed with cancer face and pose specific problems, 
including debility, weight loss, malnutrition and anaemia, that may all impact 
outcomes. This is the first study to highlight the prognostic significance of 
postoperative morbidity severity classification after D2 gastrectomy for 
carcinoma. The principal findings supported the working hypothesis and 
showed that the one third of patients who suffered any complication were 40% 
less likely to enjoy disease free 5-year survival. The poorer survival 
associated with post-operative complications was independent of tumour 
histopathological stage, suggesting that treatment strategies aimed at 
minimizing complications may not only improve oncological outcome, but also 
reduce lengths of hospital stay, improve quality of life, with allied consequent 
economic benefits for hospital services and prudent NHS healthcare. 
Patients carrying significant comorbidities, poor functional 
performance, and higher risk assessment profiles are well recognized to 
suffer poorer post-operative quality of life and cumulative survival following 
abdominal surgery.[12] Yet only recently have the associations between pre-
operative physiological functional status, and post-operative disease 
recurrence been appreciated.[2] Richards et al. reported in a cohort of 
patients from Glasgow, Scotland with pTNM stage I-III colorectal cancer, that 
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poor pre-operative POSSUM scores were fifty per cent more likely to develop 
post-operative complications and disease recurrence.[2] Similarly, Kang et al 
(South Korea),[13] Zhang et al (China), [14] Inokuchi (Tokyo) [15] have 
reported an association between pre-operative serum albumin and surgical 
complications in patients undergoing gastrectomy for cancer, which suggest 
that the systemic inflammatory response plays a pivotal role. Unfortunately, 
these latter reports focused only on serum albumin analyses, and other SIR 
biomarkers such as the C-reactive protein based modified Glasgow 
Prognostic Score, may provide better prognostic information. Indeed, in a 
recent report comparing a raft of all serum based inflammatory biomarkers, 
the modified Glasgow Prognostic Score (mGPS), was the only inflammatory 
marker independently associated with disease recurrence and overall 
survival.[16] Measures that optimize patients’ risk assessment profiles may 
offer the greatest therapeutic benefit and the magnitude of these benefits has 
been signaled in a recent report form Barberan-Garcia et al (Barcelona) who 
observed a 51% reduction in post-operative morbidity in patients undergoing 
intensive prehabilitation programs prior to major abdominal surgery.[17] 
The adverse influence of global post-operative morbidity on overall 
survival has been reported previously. Li et al. from China[1] reported 
significantly poorer 5-year overall survival in a cohort of 432 patients when 
morbidity occurred (21.8%) compared with controls (39.9%), which was 
independent of confounding factors (HR 2.5. p<0.001). However, the value of 
overall survival as an outcome measure is relatively limited because of the 
inclusion of non-cancer related deaths in the analysis, diluting the prognostic 
influence of cancer biology. In contrast, septic complications after surgery 
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have been implicated in influencing disease-free survival.[18-19] Both 
Tokunga et al.[18] (n=756) and Hayashi et al.[19] (Japan) (n=502) contended 
that sepsis was associated with poorer disease-free 5-year survival of the 
order of 20% (HR 2.22, p=0.002), and 25% (HR 1.96, p=0.013) respectively. 
The findings of this study are not in keeping with the above, but are in line 
with those reported by Nelen et from the Netherlands[20] with sepsis 
associated with 33.1% poorer disease-free 5-year survival. Moreover, 
respiratory sepsis was four-fold greater in western cohorts (20%)[20] when 
compared with eastern cohorts (5%).[19] 
There are a number of inherent limitations and potential criticisms of 
this study. Data related to patients' race, body mass indices and detailed 
comorbidity was not collected prospectively, and was therefore not available 
for analysis as confounding factors. The patient cohort studied is a selected 
group (most had undergone a potentially curative R0 gastrectomy) and was 
not representative of all gastric cancer patients; indeed, only approximately 
one third of South Wales patients undergo potentially curative resection.[21] 
In contrast, the study has several strengths, benefiting from robust follow-up 
data with accurate causes and dates of death obtained from the office of 
national statistics; over 75% were followed up for at least 5 years or death. 
Patients were recruited consecutively from a single UK geographical region, 
and all had been treated by the same multidisciplinary team and group of 
specialist surgeons, using a standardized staging algorithm and operative 
technique, with extensive audited and published quality control. Moreover, the 
findings cannot be criticized because of poor surgical outcomes, which 
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compare favorably with national trial and audit data in terms of post-operative 
morbidity and cumulative survival. [5-6] 
In conclusion, the concept of surgical prehabilitation refers to an 
emerging field of research concerned with strategies to optimise patients’ 
preoperative physical and psychosocial risk profiles, such that postoperative 
recovery trajectories are boosted, resulting in fewer complications, shorter 
durations of hospital stay, improved quality of life, and cost effective prudent 
health care. Reports to date have focused on a heterogenous group of health 
interventions, applied within the care continuum, and occurring between 
diagnosis and the start of surgical treatment. These have included, education, 
exercise, nutrition, and psychosocial approaches, focused not only the 
patient, but also the patient’s family, with the aim of promoting health related 
behavioural change that reaches beyond the immediate preoperative period 
into the future and longer term. Prehabilitation is the logical precursor to ERPs 
but should comprise more than just exercise. Nutritional and psychosocial 
wellbeing are also critical aspects of perioperative care and key components 
of prehabilitation programmes. The preoperative period presents an 
opportunity to utilize a so-called ‘teachable moment’ and emphasize the 
importance of positive lifestyle change such as smoking cessation. Future 
research efforts should explore combining and fusing prehabilitation with 
ERPs to catalyze additional improvements in outcomes. Moreover, cost-
effectiveness evaluation should form part of future research. Prehabilitation in 
specialties with high risk profiles will probably be associated with additional 
costs, though it is possible, if not likely, that such costs would be offset by 
improved outcomes such as shorter durations of hospital stay, fewer 
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complications, and better quality of life. Finally and by tradition, prehabilitation 
programs are prescriptive and generic; employing a one size fits all 
philosophy. Bespoke personalized programs, related to individual patients’ 
physiological, functional, psychosocial profiles, and including combinations of 
supervised and independent self assessed exercises, delivered in the 
community rather than secondary care are likely to be associated with greater 
compliance and effect. 
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Tables 
Table 1. The relationship between tumour related factors, overall survival and 
disease free survival in patients undergoing potentially curative resection for 
gastric cancer.  
 
  Disease free 
survival 
 Overall 
survival 
 
Clinicopathological 
variables 
Frequency 
n (%) 
5 year survival 
rate (%) 
p-value 5 year survival 
rate (%) 
p-value 
Age (years) 
    <65 
     65 – 75 
    > 75 years 
 
125 (33.5) 
163 (43.7) 
85 (22.8) 
 
50.0 
50.8 
60.7 
 
0.371 
 
51.1 
55.0 
60.7 
 
0.507 
Sex  
    Female 
    Male 
 
119 (31.9) 
254 (68.1) 
 
49.4 
54.3 
 
0.446 
 
53.9 
55.4 
 
0.815 
Tumour Site 
     Proximal 
     Body 
     Distal 
 
124 (33.2) 
86 (23.1) 
163 (43.7) 
 
35.4 
65.7 
57.3 
 
<0.001 
 
39.0 
65.7 
59.7 
 
0.002 
T category 
     1 
     2 
     3 
     4 
 
88 (23.6) 
28 (7.5) 
134 (35.9) 
123 (33.0) 
 
83.8 
81.3 
48.8 
30.2 
 
<0.001 
 
83.8 
87.5 
50.5 
33.3 
 
<0.001 
N category 
     0 
     1 
     2 
     3 
 
167 (44.8) 
76 (20.4) 
72 (19.3) 
58 (15.5) 
 
73.1 
49.0 
31.3 
15.0 
 
<0.001 
 
74.6 
51.0 
33.3 
20.0 
 
<0.001 
Tumour Stage 
     I    
     II 
     III 
 
100 (26.8) 
119 (31.9) 
154 (41.3) 
 
85.1 
58.1 
25.5 
 
<0.001 
 
85.1 
62.4 
27.4 
 
<0.001 
Differentiation 
     Well/Moderate 
     Poor 
 
188 (50.4) 
185 (49.6) 
 
60.8 
43.8 
 
0.005 
 
62.9 
46.2 
 
0.005 
Vascular invasion 
     No 
     Yes 
 
220 (59.0) 
153 (41.0) 
 
64.8 
28.6 
 
<0.001 
 
66.5 
31.9 
 
<0.001 
R status 
     0 
     1 
 
317 (85.0) 
56 (15.0) 
 
61.2 
14.7 
 
<0.001 
 
58.7 
14.7 
 
<0.001 
Neoadjuvant 
therapy 
     No 
     Yes 
 
 
299 (80.2) 
74 (19.8) 
 
 
55.7 
37.2 
 
 
0.026 
 
 
57.8 
39.5 
 
 
0.027 
Adjuvant therapy 
     No  
     Yes 
 
295 (79.1) 
78 (20.9) 
 
54.9 
40.0 
 
0.080 
 
57.1 
42.5 
 
0.087 
Post-operative 
morbidity 
     No 
     Yes 
 
 
246 (66.0) 
127 (34.0) 
 
 
59.5 
35.9 
 
<0.001 
 
 
61.5 
38.5 
 
0.001 
Infective 
complication 
     No 
     Yes 
 
299 (80.2) 
74 (19.8) 
 
54.6 
43.5 
 
0.167 
 
56.4 
47.8 
 
0.287 
Non-infective 
complication 
     No 
     Yes 
 
 
351 (94.1) 
22 (5.9) 
 
 
53.8 
27.3 
 
0.084 
 
 
56.1 
27.3 
 
0.060 
Clavien-Dindo      
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classification 
     0 
     1 
     2 
     3 
     4 
     5 
 
246 (66.0) 
21 (5.6) 
57 (15.3) 
27 (7.2) 
13 (3.5) 
9 (2.4) 
 
59.5 
42.9 
38.5 
37.5 
33.3 
0.00 
0.007  
61.5 
42.9 
43.6 
37.5 
33.3 
0.0 
0.006 
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Table 2. The incidence of complications in patients undergoing potentially 
curative resection for gastric cancer.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classification of complications   
Infective complications 74 (19.8%) 
Surgical site infection 
     Anastomotic leak 
     Duodenal leak 
     Intra-abdominal abscess 
     Wound 
     Enterocutaneous Fistula 
 
18 (4.8%) 
5 (1.3%) 
3 (0.8%) 
18 (4.8%) 
2 (0.5%) 
Extra-abdominal infection 
     Pneumonia 
     Urinary tract infection 
 
24 (6.9%) 
3 (0.9%) 
Non-infective complications 22 (5.9%) 
 
Cardiovascular 
     Acute coronary syndrome 
     Atrial fibrillation 
 
2 (0.5%) 
2 (0.5%) 
 
Respiratory 
     Pulmonary embolus 
     Pulmonary oedema 
     Pleural effusion 
 
2 (0.5%) 
0 (0.0%) 
4 (1.1%) 
Miscellaneous 12 (3.6%) 
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Table 3. The relationship between post-operative morbidity and 
clinicopathological factors in patients undergoing potentially curative resection 
for gastric cancer.  
 
Clinicopathological 
variables 
No complication 
n (%) 
Complication 
n (%) 
p-value 
Age (years) 
    <65 
     65 – 75 
    > 75 years 
 
87 (35.4) 
104 (42.3) 
55 (22.4) 
 
37 (29.4) 
59 (46.8) 
30 (23.8) 
 
0.504 
Sex  
    Female 
    Male 
 
76 (30.9) 
170 (69.1) 
 
43 (34.1) 
83 (65.9) 
 
0.527 
Tumour Site 
     Proximal 
     Body 
     Distal 
 
71 (28.9) 
66 (26.8) 
109 (44.3) 
 
53 (41.7) 
20 (15.7) 
54 (42.5) 
 
0.013 
T category 
     1 
     2 
     3 
     4 
 
68 (27.6) 
16 (6.5) 
84 (34.1) 
78 (31.7) 
 
21 (16.5) 
12 (9.4) 
49 (38.6) 
45 (35.4) 
 
0.106 
N category 
     0 
     1 
     2 
     3 
 
125 (50.8) 
46 (18.7) 
40 (16.3) 
35 (14.2) 
 
43 (33.9) 
29 (22.8) 
32 (25.2) 
23 (18.1) 
 
0.016 
Tumour Stage 
     I    
     II 
     III 
 
76 (30.9) 
78 (31.7) 
92 (37.4) 
 
25 (19.7) 
40 (31.5) 
62 (48.8) 
 
0.038 
Differentiation 
     Well/Moderate 
     Poor 
 
124 (50.4) 
122 (49.6) 
 
64 (50.4) 
63 (49.6) 
 
0.998 
Vascular invasion 
     No 
     Yes 
 
157 (63.8) 
89 (36.3) 
 
63 (49.6) 
64 (50.4) 
 
0.008 
R status 
     0 
     1 
 
221 (89.8) 
25 (10.2) 
 
96 (75.6) 
31 (24.4) 
 
<0.001 
Neoadjuvant therapy 
     No 
     Yes 
 
196 (79.7) 
50 (20.3) 
 
103 (81.7) 
23 (18.3) 
 
0.634 
Adjuvant therapy 
     No  
     Yes 
 
196 (79.7) 
50 (20.3) 
 
99 (78.6) 
27 (21.4) 
 
0.804 
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Table 4: Univariable and multivariable analysis of clinicopathological factors and complication markers; disease free and overall 
survival  
 Univariable  Multivariable  Univariable  Multivariable  
 Disease free survival    Overall survival    
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
Age (Years) 
<65 / 66-75 / >75) 
 
0.77 (0.57 – 1.02) 
 
0.072 
   
0.89 (0.71 – 1.11) 
 
0.298 
  
Gender 
(Female / Male) 
 
0.63 (0.41 – 0.96) 
 
0.031 
  
0.063 
 
0.98 (0.69 – 1.39) 
 
0.894 
  
Tumour site 
(Proximal / Body / Distal) 
 
0.76 (0.59 – 0.97) 
 
0.028 
  
0.738 
 
0.77 (0.63 – 0.94) 
 
0.009 
 
0.79 (0.65 – 0.96) 
 
0.020 
Neoadjuvant therapy 
(No / Yes) 
 
1.60 (0.99 – 2.58) 
 
0.053 
   
1.40 (0.95 – 2.07) 
 
0.093 
  
Pathological factors         
T category 
(1 / 2 / 3 / 4) 
 
2.19 (1.70 – 2.82) 
 
<0.001 
 
1.80 (1.35 – 2.39) 
 
<0.001 
 
1.93 (1.60 – 2.32) 
 
<0.001 
 
1.67 (1.34 – 2.06) 
 
<0.001 
N category 
(0 / 1 / 2 / 3) 
 
1.82 (1.52 – 2.18) 
 
<0.001 
 
 
 
0.081 
 
1.66 (1.44 – 1.92) 
 
<0.001 
 
 
 
0.068 
TNM stage 
(I / II / III) 
 
3.14 (2.24 – 4.41) 
 
<0.001 
 
 
 
0.574 
 
2.49 (1.95 – 3.18) 
 
<0.001 
  
0.567 
Differentiation  
(Moderate / Poor) 
 
2.14 (1.39 - 3.30) 
 
0.001 
  
0.369 
 
1.86 (1.33 - 2.61) 
 
<0.001 
 
 
 
0.089 
Vascular invasion  
(No / Yes)  
 
3.36 (2.19 - 5.16) 
 
<0.001 
 
1.87 (1.17 – 2.97) 
 
0.008 
 
2.96 (2.12 - 4.15) 
 
<0.001 
 
1.76 (1.21 – 2.55) 
 
0.003 
R status  
(0 / 1) 
 
4.19 (2.67 – 6.58) 
 
<0.001 
 
2.14 (1.32 – 3.45) 
 
0.002 
 
3.27 (2.25 – 4.76) 
 
<0.001 
  
0.619 
Post-operative factors         
Adjuvant therapy 
(No / Yes) 
 
1.56 (0.96 – 2.53) 
 
0.070 
   
1.39 (0.93 – 2.06) 
 
0.105 
  
Post-operative morbidity 
(No / Yes) 
 
2.17 (1.42 – 3.31) 
 
<0.001 
 
1.63 (1.06 – 2.50) 
 
0.026 
 
2.28 (1.63 – 3.17) 
 
<0.001 
 
2.25 (1.04 – 4.85) 
 
0.039 
Infective complication 
(No / Yes) 
 
1.30 (0.77 – 2.18) 
 
0.328 
   
1.42 (0.95 – 2.12) 
 
0.084 
  
Non-infective complication 
(No / Yes) 
 
2.06 (0.90 – 4.72) 
 
0.089 
   
3.54 (2.03 – 6.17) 
 
<0.001 
  
0.061 
Clavien-Dindo classification 
(0 / 1 / 2 / 3 / 4 / 5)     
 
1.27 (1.08 – 1.50) 
 
0.004 
  
0.197 
 
1.50 (1.33 – 1.79) 
 
<0.001 
 
1.76 (1.35 – 2.29) 
 
<0.001 
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Table 5A. Clinicopathological factors and survival in stage I&II gastric cancer 
 Univariable  Multivariable  Univariable  Multivariable  
 Disease free survival    Overall survival    
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
Age (Years) 
<65 / 66-75 / >75) 
 
0.72 (0.44 – 1.17) 
 
0.186 
   
1.09 (0.76 – 1.56) 
 
0.648 
  
Gender 
(Female / Male) 
 
0.99 (0.47 – 2.10) 
 
0.981 
  
 
 
1.21 (0.66 – 2.19) 
 
0.540 
  
Tumour site 
(Proximal / Body / Distal) 
 
0.61 (0.40 – 0.93) 
 
0.022 
  
0.231 
 
0.67 (0.49 – 0.92) 
 
0.013 
 
0.68 (0.50 – 0.93) 
 
0.014 
Neoadjuvant therapy 
(No / Yes) 
 
2.29 (1.05 – 5.00) 
 
0.037 
  
0.662 
 
1.92 (1.04 – 3.54) 
 
0.037 
  
0.961 
Pathological factors         
T category 
(1 / 2 / 3 / 4) 
 
1.89 (1.34 – 2.65) 
 
<0.001 
 
 
 
0.845 
 
1.48 (1.16 – 1.89) 
 
0.001 
 
 
 
0.902 
N category 
(0 / 1 / 2 / 3) 
 
2.92 (1.74 – 4.92) 
 
<0.001 
 
 
 
0.310 
 
1.64 (1.02 – 2.62) 
 
0.039 
 
 
 
0.711 
TNM stage 
(I / II) 
 
14.28 (3.41 – 59.85) 
 
<0.001 
 
10.13 (2.37 – 43.31) 
 
0.002 
 
3.28 (1.73 – 6.23) 
 
<0.001 
 
2.94 (1.51 – 5.74) 
 
0.002 
Differentiation  
(Moderate / Poor) 
 
1.47 (0.72 – 2.96) 
 
0.288 
  
 
 
1.07 (0.62 – 1.84) 
 
0.814 
 
 
 
 
Vascular invasion  
(No / Yes)  
 
4.23 (2.08 – 8.58) 
 
<0.001 
 
2.66 (1.26 – 5.59) 
 
0.010 
 
3.23 (1.88 – 5.56) 
 
<0.001 
 
2.33 (1.29 – 4.20) 
 
0.005 
R status  
(0 / 1) 
 
10.56 (4.65 – 23.96) 
 
<0.001 
 
4.18 (1.76 – 9.93) 
 
0.001 
 
4.42 (2.06 – 9.46) 
 
<0.001 
  
0.536 
Post-operative factors         
Adjuvant therapy 
(No / Yes) 
 
1.80 (0.78 – 4.20) 
 
0.172 
   
1.75 (0.92 – 3.24) 
 
0.090 
  
Post-operative morbidity 
(No / Yes) 
 
2.15 (1.04 – 4.43) 
 
0.038 
 
 
 
0.474 
 
2.43 (1.42 – 4.18) 
 
0.001 
 
7.06 (1.89 – 26.38) 
 
0.004 
Infective complication 
(No / Yes) 
 
1.57 (0.67 – 3.63) 
 
0.297 
   
1.84 (1.00 – 3.38) 
 
0.051 
  
Non-infective complication 
(No / Yes) 
 
1.43 (0.19 – 10.51) 
 
0.727 
   
3.20 (1.15 – 8.91) 
 
0.026 
  
0.864 
Clavien-Dindo classification 
(0 / 1 / 2 / 3 / 4 / 5)     
 
1.26 (0.93 – 1.70) 
 
0.142 
  
 
 
1.66 (1.37 – 2.00) 
 
<0.001 
 
2.93 (1.89 – 4.55) 
 
<0.001 
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Table 5B. Clinicopathological factors and survival in stage III gastric cancer 
 Univariable  Multivariable  Univariable  Multivariable  
 Disease free survival    Overall survival    
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
Age (Years) 
<65 / 66-75 / >75) 
 
0.85 (0.60 – 1.21) 
 
0.374 
   
0.86 (0.65 – 1.15) 
 
0.302 
  
Gender 
(Female / Male) 
 
0.44 (0.27 – 0.72) 
 
0.001 
 
0.44 (0.26 – 0.72) 
 
0.001 
 
0.82 (0.54 – 1.24) 
 
0.350 
  
Tumour site 
(Proximal / Body / Distal) 
 
0.92 (0.69 – 1.23) 
 
0.583 
  
 
 
0.97 (0.77 – 1.23) 
 
0.801 
 
 
 
 
Neoadjuvant therapy 
(No / Yes) 
 
1.13 (0.63 – 2.02) 
 
0.683 
   
0.94 (0.58 – 1.54) 
 
0.814 
  
Pathological factors         
T category 
(1 / 2 / 3 / 4) 
 
1.58 (0.92 – 2.71) 
 
0.097 
 
 
 
 
 
1.63 (1.06 – 2.53) 
 
0.028 
 
 
 
 
N category 
(0 / 1 / 2 / 3) 
 
1.26 (0.88 – 1.80) 
 
0.202 
 
 
 
 
 
1.30 (0.97 – 1.73) 
 
0.079 
 
 
 
0.051 
Differentiation  
(Moderate / Poor) 
 
1.82 (1.06 – 3.13) 
 
0.031 
 
1.91 (1.11 – 3.30) 
 
0.020 
 
1.87 (1.20 – 2.91) 
 
0.006 
 
1.80 (1.15 – 2.84) 
 
0.011 
Vascular invasion  
(No / Yes)  
 
1.79 (1.05 – 3.07) 
 
0.033 
 
1.84 (1.07 – 3.15) 
 
0.027 
 
1.55 (1.02 – 2.37) 
 
0.041 
 
 
 
0.063 
R status  
(0 / 1) 
 
1.64 (0.96 – 2.78) 
 
0.069 
 
 
 
 
 
1.61 (1.05 – 2.47) 
 
0.031 
  
0.328 
Post-operative factors         
Adjuvant therapy 
(No / Yes) 
 
1.13 (0.64 – 2.00) 
 
0.676 
   
0.95 (0.59 – 1.54) 
 
0.844 
  
Post-operative morbidity 
(No / Yes) 
 
1.44 (0.87 – 2.38) 
 
0.158 
 
 
 
 
 
1.74 (1.16 – 2.60) 
 
0.007 
 
 
 
0.770 
Infective complication 
(No / Yes) 
 
0.99 (0.52 – 1.91) 
 
0.982 
   
1.14 (0.69 – 1.89) 
 
0.606 
  
Non-infective complication 
(No / Yes) 
 
1.44 (0.58 – 3.61) 
 
0.432 
   
2.74 (1.41 – 5.29) 
 
0.003 
 
2.24 (1.10 – 4.53) 
 
0.025 
Clavien-Dindo classification 
(0 / 1 / 2 / 3 / 4 / 5)     
 
1.10 (0.90 – 1.35) 
 
0.338 
   
1.28 (1.10 – 1.49) 
 
0.001 
 
1.21 (1.04 – 1.42) 
 
0.015 

  
29 
29 
Figures 
Figure 1 The relationship between post-operative compilation, disease free and overall 
survival 
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Figure 2 The relationship between post-operative complication, disease free and overall 
survival in patients with stage I&II gastric cancer. 
 
 
 
A. Disease free survival in patients with TNM stage I&II gastric cancer, B. Overall survival 
in patients with TNM stage I&II gastric cancer, C. Disease free survival in patients with 
TNM stage III gastric cancer, D. Overall survival in patients with TNM stage III gastric 
cancer. 
